KAITLYN MAE REXROAT
Prescription History 1881213213
Physician Assistant in Lillington, NC


Quality Rating: 87.95 out of 100 score

NPI Status: Active since April 15, 2020

Contact Information

4350 US 421 S
LILLINGTON, NC
ZIP 27546
Phone: (910) 893-1210

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for KAITLYN MAE REXROAT, an active Physician Assistant specialist practicing in Lillington, NC. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 193 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol, which accounts for 69 claims alone.

Medication Index


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 20
30-Day Fills 50.6
Days Supply 1,512
NC State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills89.0
Peer Average Days Supply2,634
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $221.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.07

State Avg Cost Per Claim

$11.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Estradiol

Generic Formulation: EstradiolSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 69
30-Day Fills 162.1
Days Supply 4,854
NC State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills70.5
Peer Average Days Supply2,100
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 130.0% higher than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,040.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$58.55

State Avg Cost Per Claim

$67.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Fluconazole

Generic Formulation: FluconazoleSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 51
NC State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.1
Peer Average Days Supply236
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $119.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.17

State Avg Cost Per Claim

$11.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.

Therapeutic Applications

Fluconazole is used to treat vaginal yeast infections. It works by stopping the growth of common types of vaginal yeast (fungus). This medication belongs to a class of drugs called azole antifungals.

Metronidazole

Generic Formulation: MetronidazoleSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 147
NC State Average Benchmarks
Peer Average Claims14.0
Peer Average 30-Day Fills14.0
Peer Average Days Supply48
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 50.0% more claims than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $166.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.92

State Avg Cost Per Claim

$18.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.

Therapeutic Applications

This medication is used on the skin to treat a certain skin disorder known as rosacea, a type of adult acne. It may help to decrease redness, swelling and the number of pimples caused by rosacea. This medication is an antibiotic. For the treatment of rosacea, metronidazole is believed to work by decreasing swelling (inflammation). Some brands of this medication also contain sunscreens (see also Notes section).

Mometasone Furoate

Generic Formulation: Mometasone FuroateSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 11
30-Day Fills 12.8
Days Supply 339
NC State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills29.4
Peer Average Days Supply746
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.0% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $172.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.66

State Avg Cost Per Claim

$56.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders.

Therapeutic Applications

Mometasone is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. Mometasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 19
30-Day Fills 39.0
Days Supply 1,170
NC State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills62.7
Peer Average Days Supply1,787
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.8% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,280.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$962.15

State Avg Cost Per Claim

$613.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 40
30-Day Fills 92.0
Days Supply 2,765
NC State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills34.6
Peer Average Days Supply1,022
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 110.5% higher than the standard regional baseline profile for NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,605.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$440.14

State Avg Cost Per Claim

$386.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like KAITLYN MAE REXROAT provides transparency into local medical care patterns within Lillington, NC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Physician Assistant** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.